Last checked at 31 Mar 2023 16:39
TRADING UPDATES: FireAngel signs with British Gas; Shanta pours gold
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
ValiRx Share News (VAL)
VAL Share
Price
VAL Share
News
VAL Share
Chat2
VAL Share
Trades9
VAL
Live RNS
VAL Share
Charts
VAL Level 2
Console
VAL Live
Share Price
VAL Broker
Ratings
VAL Directors
Deals
VAL Financial
Diary
VAL
Fundamentals
VAL Short
Positions
VAL
Media
ValiRx Information
Share Price Information for ValiRx (VAL)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
3.25
Bid:
3.20
Ask:
3.30
Change:
0.00 (0.00%)
Spread:
0.10 (3.125%)
Open:
3.25
High:
3.25
Low:
3.25
Prev. Close:
3.25
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.ValiRx secures 'substantial amendment' to VAL201 clinical trials
Thu, 20th Jun 2019 09:54
(Sharecast News) - Clinical stage biotechnology company ValiRx updated the market on 'VAL201' on Thursday, confirming that, based on clinical results, a "substantial amendment" to the clinical trial protocol had received regulatory approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) and the research ethics committee.The AIM-traded firm said that, following the approval of the amendment, prostate cancer specialist Dr Mark Linch had been appointed as principal investigator to the clinical trial team at University College London Hospital (UCLH).Dr Linch was an honorary senior lecturer at the University College London (UCL) Cancer Institute, where he was leading the uro-oncology biology group, and was also a consultant medical oncologist specialising in the treatment of prostate and bladder cancer at UCLH.ValiRx confirmed that Dr Rebecca Kristeleit was continuing with the study as chief investigator.It said that to date, the results generated by the trial - aided by sizable analytical method developments - had shown that safe toxicological limits could be significantly elevated and applied to much higher levels in humans than was suggested by the preclinical studies.The approval given to relax the restrictions previously applied to the trial would mean that a more effective use of VAL201 could be achieved with respect to concentration and timing, and regarding increased flexibility in the administration of the drug, the board explained.Additionally, it said the amendment relating to dosing strategies meant that - in light of accumulated clinical data - the company would be able to develop further protocols.Those would be designed to evaluate a range of defined therapeutic approaches that were to be tested against each other, to determine the most effective approach in terms of disease management, cost effectiveness and patient welfare in further clinical trials.The protocols would be the precursor to seeking approval to conduct trials aimed at gaining sufficient data to secure partnering and then marketing approval application.ValiRx reported that the trial thus far had met all of its primary and secondary endpoints, with the safety and tolerability results continuing to be acceptable, and further evidence of the compound's positive effect in reducing the progress of prostate cancer witnessed.The data from the trial was currently being collated for examination by independent third party experts.ValiRx said the approval of the amendment further validated its clinical development throughout VAL201's first-in-human trial.Further information connected to the data, and the results and findings from the trial, would form the basis of a report outlining the compound's clinical profile and behaviour, which would be published in due course."This substantial amendment has taken a lot of effort from the whole team both internal and by all our service providers to achieve," said ValiRx chief operating officer Dr George Morris."The most gratifying thing is that our original pre-clinical experimental data has held up well and been vindicated throughout the whole of this first-in-human trial."Now, as the trial is delivering an extensive and positive output, it is also providing practical information back to the trialling of VAL201, so that the next stage of clinical development, in which we will endeavour to show how effective the compound actually is, can be entered into with confidence and support from all those involved."
More News
1 Mar 2023 20:09
TRADING UPDATES: Ediston signs 10-year lease with Marks & Spencer
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:
Read more1 Mar 2023 14:26
ValiRx incorporates new wholly-owned lab subsidiary
(Sharecast News) - Life science company ValiRx announced the incorporation of a new wholly-owned subsidiary, Inaphaea BioLabs, on Wednesday.
Read more3 Feb 2023 13:41
TRADING UPDATES: Somero revenue short of outlook; SigmaRoc optimistic
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:
Read more26 Jan 2023 15:44
UK shareholder meetings calendar - next 7 days
| Friday 27 January | |
| Avon Protection PLC | AGM |
| Henderson Far East Income Ltd | AGM |
| Ixico PLC | AGM |
| NB Global Monthly Income Fund Ltd | EGM re proposed managed wind-down |
| On The Beach Group PLC | AGM |
| Pathfinder Minerals PLC | GM re capital raise |
| Serica Energy PLC | GM re consideration shares approval |
| Treatt PLC | AGM |
| Monday 30 January | |
| Bluebird Merchant Ventures Ltd | AGM |
| Contango Holdings PLC | AGM |
| Hollywood Bowl Group PLC | AGM |
| SkinBioTherapeutics PLC | GM re annual report review |
| Starwood European Real Estate Finance Ltd | EGM re capital return |
| Webis Holdings PLC | AGM |
| Tuesday 31 January | |
| Hydrogen Future Industries PLC | AGM |
| Mobile Streams PLC | AGM |
| Residential Secure Income PLC | AGM (TBC) |
| Star Phoenix Group Ltd | GM re removal and appointment of auditor |
| Team PLC | AGM |
| Yamana Gold Inc | SGM re transaction with Agnico Eagle Mines Ltd and Pan American Silver Corp |
| Zamaz PLC | AGM |
| Wednesday 1 February | |
| Baronsmead Second Venture Trust PLC | AGM |
| Baronsmead Venture Trust PLC | AGM |
| Capricorn Energy PLC | GM re directors removal and appointment of new directors |
| Catalyst Media Group | AGM |
| Hyve Group PLC | AGM |
| Imperial Brands PLC | AGM |
| Premier Miton Group PLC | AGM |
| Renew Holdings PLC | AGM |
| Schroder Asia Pacific Fund PLC | AGM |
| Thursday 2 February | |
| abrdn Equity Income Trust PLC | AGM |
| Alteration Earth PLC | AGM |
| Baillie Gifford European Growth Trust PLC | AGM |
| JPMorgan Indian Investment Trust PLC | AGM |
| Sage Group PLC | AGM |
| Schroder European Real Estate Investment Trust PLC | AGM |
| Tectonic Gold PLC | AGM |
| ValiRx PLC | GM re fundraising |
| Copyright 2023 Alliance News Ltd. All Rights Reserved. | |
17 Jan 2023 21:40
TRADING UPDATES: Future Metals in JV; Gunsynd sells stake in investee
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:
Read more13 Jan 2023 13:31
IN BRIEF: ValiRx seeks up to GBP1.5 million for new research facility
ValiRx PLC - Hatfield Heath, England-based life sciences company focused on early-stage cancer therapeutics and women's health - Raises GBP1 million from placing of 9.1 million shares at 11 pence each. Also will raise up to GBP500,000 more from a broker offer to retail investors at the same price. Turner Pope Investments Ltd will run the broker offer. Every four shares in the placing and retail offer come with a warrant to buy another new share at 14p over the next three years. Calls February 2 general meeting to approve the fund raise. Currently has a GBP10.1 million market capitalisation.
Read more6 Dec 2022 11:31
ValiRx shares fall on test extension, but optimistic of other assets
(Alliance News) - ValiRx PLC on Tuesday saw shares drop, after extending its evaluation agreement with Hokkaido University to conduct further experimental testing.
Read more24 Oct 2022 12:47
ValiRx forms new majority-owned breast cancer subsidiary
(Sharecast News) - Women's health and cancer therapeutics company ValiRx announced the formation of a new partially-owned subsidiary, Cytolytix, on Monday, which had signed an intellectual property licence agreement with King's College London (KCL).
Read more24 Oct 2022 10:05
ValiRx teams with King's College London for cancer project
(Alliance News) - ValiRx PLC on Monday said it is making progress on its goal to introduce new academic projects into its portfolio, after launching subsidiary company Cytolytix Ltd and signing a licence agreement with King's College London.
Read more8 Sep 2022 11:47
IN BRIEF: ValiRx shares up on new interim chief scientific officer
ValiRx PLC - Nuneaton, England-based drug development company - Appoints Catherine Tralau-Stewart as interim chief scientific officer. Says she has experience working across leading pharmaceutical companies and academic groups. Tralau-Stewart will review new, incoming science; enhance the progress of existing projects; and influence the overall strategic scientific direction of the company, ValiRx adds. Chief Executive Suzy Dilly comments: "I'm looking forward to having another in-house scientist with whom to share ideas and to develop and deliver upon our strategic ambitions. Cathy's wealth of experience in exactly the areas in which we wish to progress, makes her an excellent choice for this role."
Read more31 Aug 2022 13:51
EARNINGS UPDATES: Windward widens loss as operating expenses rise
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:
Read more13 Jul 2022 14:44
IN BRIEF: ValiRx shares jump on breast cancer drug candidate progress
ValiRx PLC - Nuneaton, England-based drug development company - Completes the evaluation of the impact of a peptide drug candidate against triple negative breast cancer. Evaluation concludes there is "good evidence" of biological activity and a "strong" rationale for further development. Adds that the drug candidate was investigated over nine months. Tests also demonstrate promising data on ovarian cancer cells, in addition to the targeted breast cancer cells. As a result, ValiRx has notified the academic team and intellectual property & licensing team at King's College London that it wants to proceed to full in-licensing.
Read more5 Jul 2022 15:51
IN BRIEF:ValiRx gains GBP1.0 million from Turner Pope broker option
ValiRx PLC - Nuneaton, England-based drug development company - Announces that the broker option granted to Turner Pope Investments Ltd has been fully subscribed and raises GBP1.0 million before expenses.
Read more30 Jun 2022 17:31
TRADING UPDATES: M&C Saatchi expects to deliver on annual profit
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:
Read more